Exicure, Inc. (XCUR)
| Market Cap | 4.85M |
| Revenue (ttm) | 23.79M |
| Net Income (ttm) | 3.07M |
| Shares Out | 8.65M |
| EPS (ttm) | 1.68 |
| PE Ratio | 0.35 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,705 |
| Open | 0.570 |
| Previous Close | 0.571 |
| Day's Range | 0.561 - 0.596 |
| 52-Week Range | 0.365 - 1.500 |
| Beta | 1.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 30, 2024 |
About XCUR
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. [Read more]
Financial Performance
Financial StatementsNews
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
CHICAGO--(BUSINESS WIRE)--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company ...
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on November 22, 2023...
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. announces appointment of new CEO and CFO and changes to Board of Directors.
Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. reports second quarter 2023 financial results and provides corporate update.
Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. reports first quarter 2023 financial results and provides corporate update.
Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonuclei...
Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld
CHICAGO--(BUSINESS WIRE)--Exicure has invested in Cyworld Z Co. Ltd. through the purchase of $1 million aggregate principal amount of convertible bonds issued by Cyworld Z.
Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update
CHICAGO--(BUSINESS WIRE)--Exicure, Inc., reported financial results for the year ended December 31, 2022 and provided an update on its business strategy and corporate progress.
Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors
CHICAGO--(BUSINESS WIRE)--Exicure today announced the closing of the previously-announced private placement transaction with CBI USA, Inc. effective February 24, 2023.
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR) an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated tar...
Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated ta...
Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives
CHICAGO--(BUSINESS WIRE)--Exicure announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value.
Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference
CHICAGO--(BUSINESS WIRE)--Exicure CEO Matthias Schroff will provide a live presentation at the 2022 Chardan Genetic Medicines Conference.
Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress
CHICAGO--(BUSINESS WIRE)--Exicure today reported financial results for the quarter ended June 30, 2022 and provided an update on its business strategy and corporate progress.
Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic ...
Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic ...
Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic ...
Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference
CHICAGO--(BUSINESS WIRE)--Exicure today announced that CEO Matthias Schroff will provide a virtual presentation at the 2022 H.C. Wainwright Global Life Sciences Conference.
Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress
CHICAGO--(BUSINESS WIRE)--Exicure today reported financial results for the quarter ended March 31, 2022 and provided an update on its business strategy and corporate progress.
Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium
CHICAGO--(BUSINESS WIRE)--Exicure, Inc.® (NASDAQ:XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic ...
Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. today announced a poster presentation at TIDES USA 2022, May 9-12, 2022.
Exicure Shares Plunge After Q4 Results Included A Going Concern Risk
Exicure Inc (NASDAQ: XCUR) has reported year-end cash, cash equivalents, and short-term investments of $48.3 million that will fund its current operations into Q4 of 2022. The Company said that it exp...
Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported full year financial ...
Did You Acquire (XCUR) Before January 7, 2021? Should Management Be Held Accountable for Investors Losses?
San Diego, California--(Newsfile Corp. - February 17, 2022) - Johnson Fistel, LLP is investigating potential claims on behalf of Exicure, Inc. ("Exicure" or the "Company") (NASDAQ: XCUR) against certa...
Exicure Shareholder Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Exicure To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile C...